Peter F. Thall’s Personal Website
Here is a
picture of me being a biostatistician, with a pen, a pad, a computer, and
everything. This is what “science” looks like in real life.
Below is a
picture of me in my youth, before all the wear-and-tear reduced me to my
website seems to require a list of hobbies. In keeping with this dubious
convention, here are some of mine:
trading Apple stock options; nonverbal canine communication; aggressively
practicing humility; intergalactic exploration; watching nearly every movie
ever made; gourmet cooking; giving terribly useful advice to people who seem to
need it; staying in hotels in cities I probably wouldn’t visit if I weren’t
attending a conference; collecting
For a copy
of my CV, click here.
New Book on Dose Finding Trials
Bayesian Designs for Phase I-II
Clinical Trials. Yuan,
Nguyen, and Thall.
Chapman & Hall/CRC Biostatistics Series, 2016.
Unbiased Review: This book is a “must own” for
absolutely everyone involved in clinical trials. It is chock-full of deep wisdom, astonishing
insights, and innovative clinical trial designs. It certainly would make a
great birthday or holiday present, and would look impressive on your bookshelf
or coffee table. You probably should buy
at least two copies, in case your dog decides to see what it tastes like and
chews it up, or one of your colleagues borrows it and never returns it.
If you want
to read some of my publications, click on the links below. All of them are about statistics, medicine,
or clinical trials, and most are astonishingly well written. If you like one of them, be sure to tell your
friends and relatives about it.
Random Measures With Aftereffects, Annals of Probability, 1978
A theorem on regular infinitely
divisible Cox processes. Stochastic Processes and Their Applications 16:
Two-stage selection and testing
designs for comparative clinical trials, Biometrika, 1988
Analysis of recurrent events:
nonparametric methods for random interval count data. JASA 83: 339-347, 1988
regression models for longitudinal interval count data. Biometrics 44: 197-209,
Some covariance models
for longitudinal count data with overdispersion.
Biometrics 46: 657-671, 1990.
Test-based variable selection via cross-validation. J
Computational and Graphical Stat 1: 41-61, 1992
Practical Bayesian guidelines
for phase IIB clinical trials. Biometrics 50: 337-349, 1994
Bayesian sequential monitoring
designs for single-arm clinical trials with multiple outcomes. Stat in Med
Estimating genomic category
probabilities from fluorescent in situ hybridization counts with
misclassification. JRSS-C (Applied Statistics) 45:431-446, 1996
Variable selection in regression via repeated data
splitting. J Comp and Graphical Stat,
Parametric likelihoods for multiple
non-fatal competing risks and death. Stat in Med, 17:999-1016, 1998
Some extensions and applications of a Bayesian
strategy for monitoring multiple outcomes in clinical trials. Stat in Med, 17:1563-1580, 1998.
A strategy for dose finding and
safety monitoring based on efficacy and adverse outcomes in phase I/II clinical
trials. Biometrics 54:251-264, 1998.
Based on Two-Dimensional Safety and Efficacy Alternatives in Oncology Trials,
Designs for Phase II Clinical Trials with Multiple Outcomes, Biometrics 1999
Accrual strategies for phase I trials with delayed
patient outcome, Statistics in Medicine, 1999
Designs for Phase II Clinical Trials with Multiple Outcomes, Biometrics 1999
Evaluating multiple treatment
courses in clinical trials. Stat in Med,
19: 1011-1028, 2000
Evaluation of Multiple Treatment Effects, Biometrics 56: 213-219, 2000
Designs for Pre-Phase II Screening Trials in Oncology, Biometrics 2001
Dose-Finding Based on
Feasibility and Toxicity in T-cell Infusion Trials, Biometrics 2001
Selecting therapeutic strategies
based on efficacy and death in multi-course clinical trials. JASA, 97:29-39, 2002
Ethical issues in oncology biostatistics. Stat Meth in Medical Res, 11:429-448, 2002
Seamlessly Expanding a
Randomized Phase II Trial to Phase III, Biometrics, 2002
Adaptive Decision Making in a
Lymphocyte Infusion Trial, Biometrics, 2002
Monitoring the Rates of Composite
Events with Censored Data in Phase II Clinical Trials, Biometrics, 2002
Busulfan systemic exposure relative to
regimen-related toxicity and acute graft vs. host disease; defining a
therapeutic window for IVBuCy2 in chronic myelogenous leukemia. Biology of Blood and Marrow Transplantation,
approaches to phase II trials in diseases with multiple subtypes. Statistics in Medicine, 22: 763-780, 2003
Dose-finding with two agents
in phase I oncology trials. Biometrics,
Comparison of 100-day mortality rates
associated with IV busulfan and cyclophosphamide versus
other preparative regimens in allogeneic bone marrow transplant for chronic
myelogenous leukemia: Bayesian sensitivity analyses of confounded treatment and
center effects. Bone Marrow Transplantation, 33: 1191-1199, 2004.
Dose-finding based on multiple
toxicities in a soft tissue sarcoma trial.
JASA, 99:26-35, 2004
Dose-finding based on
efficacy-toxicity trade-offs. Biometrics, 60:684-693, 2004.
Determining a Maximum-Tolerated
Schedule of a Cytotoxic Agent, Biometrics 61, 335–343, 2005
Monitoring event times in early phase
clinical trials: some practical issues. Clinical Trials. 2:467-478, 2005
Adaptive dose selection using
efficacy-toxicity trade-offs: illustrations and practical considerations. J Biopharm Stat 16:623-638, 2006
A Geometric Approach to Comparing
Treatments for Rapidly Fatal Diseases, Biometrics 2006
Continuous Bayesian adaptive randomization
based on event times with covariates.
Stat in Med, 25:55-70, 2006
Simultaneously optimizing dose
and schedule of a new cytotoxic agent. Clinical Trials, 4:113-124, 2007
Bayesian and frequentist two-stage treatment
strategies based on sequential failure times subject to interval censoring.
Stat in Med 26:4687-4702,
Adaptive Therapy for Androgen-Independent
Prostate Cancer: A Randomized Selection Trial of Four Regimens, JNCI,
Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and
allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive
myeloid leukemias and myelodysplastic syndrome. Leukemia. 22:258-264, 2008
daily IV busulfan and fludarabine
(IV Bu-Flu) compares favorably with IV busulfan and cyclophosphamide
(IV BuCy2) as pretransplant conditioning therapy in
AML/MDS. Biology of Blood and Marrow Transplantation. 14:672-684, 2008
A review of phase 2-3 clinical trial
designs. Lifetime Data Analysis. 14:37-53, 2008
Determining the effective sample size of a
parametric prior. Biometrics.
Accounting for patient heterogeneity in
phase II clinical trials. Stat in Med 27:2802-2815, 2008
Monitoring late onset toxicities in
phase I trials using predicted risks.
Biostatistics. 9:442-457, 2008
Patient-Specific Dose Finding
Based on Bivariate Outcomes and Covariates, Biometrics, 2008
Bayesian adaptive model selection for
optimizing group sequential clinical trials. Stat in Med, 27:5586-5604, 2008.
Bayesian hierarchical mixture model for
platelet derived growth factor receptor phosphorylation to improve estimation of
progression-free survival in prostate cancer. JRSS-C, 59:19-34, 2010.
Utility-based optimization of
combination therapy using ordinal toxicity and efficacy in phase I/II trials.
Biometrics. 66:532-540, 2010
Evaluating the impact of prior assumptions
in Bayesian biostatistics. Statistics in
Biosciences. 2:1-17, 2010
Bayesian models and decision algorithms for complex
early phase clinical trials. Statistical Science. 25:227-244, 2010
Defining and ranking effects of individual
agents based on survival times of cancer patients treated with combination
chemotherapies. Stat in Med, 30:1777-1794, 2011.
Optimizing the concentration and bolus of
a drug delivered by continuous infusion. Biometrics. 67:1638-1646, 2011
A hybrid geometric phase II-III
clinical trial design based on treatment failure time and toxicity. J Stat
Planning and Inf. 142:944-955, 2012
progression-free survival in pediatric brain tumor patients when some
progression statuses are unknown. JRSS-C, 61:135-149, 2012
Evaluation of viable dynamic
treatment regimes in a sequentially randomized trial of advanced prostate
cancer (with discussion). JASA.
107:493-508, (with discussion, pages 509-517; rejoinder, pages 518-520),
randomization to improve utility-based dose-finding with bivariate ordinal
outcomes. J Biopharmaceutical Stat. 22:785-801, 2012.
Prior effective sample size in conditionally
independent hierarchical models. Bayesian Analysis. 7:591-614, 2012.
adaptive dose-finding based on efficacy and toxicity. J. Statistical Research.
Evaluating joint effects of
induction-salvage treatment regimes on overall survival in acute leukemia. JRSS-C. 62:67-83, 2013.
Using joint utilities of the
times to response and toxicity to adaptively optimize schedule-dose regimes.
Biometrics 69:673-682, 2013.
Using data augmentation to
facilitate conduct of phase I/II clinical trials with delayed outcomes. J American Statistical Assoc. 109:525-536, 2014.
Optimizing sedative dose in preterm
infants undergoing treatment for respiratory distress syndrome. J American Statistical Assoc. 109:931-943, 2014.
Using effective sample size for prior
calibration in Bayesian phase I-II dose-finding. Clinical Trials. 11:657-666, 2014.
A modified adaptive Lasso for
identifying interactions in the Cox model with the heredity constraint.
Statistics and Probability Letters.
Optimization of multi-stage dynamic
treatment regimes utilizing accumulated data. Statistics in Medicine,
SMART design, conduct,
and analysis in oncology. In Dynamic Treatment Regimes in Practice: Planning
Trials and Analyzing Data for Personalized Medicine. E Moodie and M. Kosorok (eds), SIAM. In press.
Some caveats for outcome
adaptive randomization in clinical trials. In Modern Adaptive Randomized
Clinical Trials: Statistical, Operational, and Regulatory Aspects. A. Sverdlov (ed).
Taylor & Francis. 2015.
Bayesian dose-finding in two
treatment cycles based on the joint utility of efficacy and toxicity. J American Statistical Assoc. 110:711-722, 2015.
estimation of targeted agent effects on biomarker change to predict clinical
outcome. Biometrics. 71:188-197, 2015.
modalities for esophageal cancer based on total toxicity burden and
disease-free survival. J Royal Statistical Society, Series C (Applied
Statistics) 65:273-297, 2016.
Theoretic Phase I-II Design for Ordinal Outcomes in Two Cycles.
Biostatistics 17:304-319, 2016.
nonparametric estimation for dynamic treatment regimes with sequential
transition times J. American Statistical Assoc. In press.
treatment comparison based on utilities of semi-competing risks in
lung cancer. J American Statistical Assoc. In press.
Utility-based designs for
randomized comparative trials with discrete outcomes. Statistics in
Medicine. In press.
A decision-theoretic comparison of treatments to
resolve air leaks after lung surgery based on nonparametric modeling. Bayesian Analysis. In press.
Parametric dose standardization
for two-agent combinations in a phase I-II trial with ordinal outcomes. J Royal Statistical Society, Series C
(Applied Statistics). In press.